08/165026 attachment to Pores # 9

=> s adenovirus? and superoxide dismutase?

2843 ADENOVIRUS? 2291 SUPEROXIDE

1251 DISMUTASE?

1218 SUPEROXIDE DISMUTASE?

(SUPEROXIDE (W) DISMUTASE?)

L1 128 ADENOVIRUS? AND SUPEROXIDE DISMUTASE?

=> s 11 and vector?

67432 VECTOR?

L2 118 L1 AND VECTOR?

=> s 12 and neuro?

22218 NEURO?

L3 44 L2 AND NEURO?

=> s 13 and treat?

549433 TREAT?

L4 43 L3 AND TREAT?

=> d 14,1-43,cit

- 1. 5,773,586, Jun. 30, 1998, Conjugates comprising truncated keratinocyte growth factor (KGF) having increased biological activity and a toxin; Denis J. Gospodarowicz, et al., 530/399; 435/69.1, 69.7; 530/350, 402 [IMAGE AVAILABLE]
- 2. 5,756,338, May 26, 1998, Aspergillus niger vacuolar aspartyl protease; Frank Buxton, et al., 435/219, 254.3; 536/23.2 [IMAGE AVAILABLE]
- 3. 5,747,035, May 5, 1998, Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor; Leonard G. Presta, et al., 424/144.1, 130.1, 133.1, 135.1, 141.1, 143.1, 153.1, 154.1, 173.1; 514/2, 8, 885; 530/387.1 [IMAGE AVAILABLE]
- 4. 5,744,131, Apr. 28, 1998, Sequence-directed DNA-binding molecules compositions and methods; Cynthia A. Edwards, et al., 424/78.08; 436/501; 514/1 [IMAGE AVAILABLE]
- 5. 5,739,277, Apr. 14, 1998, Altered polypeptides with increased half-life; Leonard G. Presta, et al., 530/326, 300, 350, 387.1 [IMAGE AVAILABLE]
- 6. 5,738,990, Apr. 14, 1998, Sequence-directed DNA-binding molecules compositions and methods; Cynthia A. Edwards, et al., 435/6, 69.1, 172.3, 320.1; 536/24.1; 935/36, 39 [IMAGE AVAILABLE]
- 7. 5,736,516, Apr. 7, 1998, Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein protein; Jean-Claude Louis, 514/12; 435/69.1, 69.4; 530/391.9, 399 [IMAGE AVAILABLE]

8. 5,736,135, Appendix 1998, Method for making variant creted proteins with altered properties; David V. Goeddel, et al., 424,34.64, 94.63; 435/212, 226, 252.3, 325, 348, 359, 365, 369, 419; 536/23.2 [IMAGE AVAILABLE]

4120

- 9. 5,731,168, Mar. 24, 1998, Method for making heteromultimeric polypeptides; Paul J. Carter, et al., 435/69.1, 69.7, 70.1, 71.1, 172.1, 172.3; 530/300, 350, 387.1, 387.3; 536/23.1, 23.4, 23.5, 23.53 [IMAGE AVAILABLE]
- 10. 5,726,014, Mar. 10, 1998, Screening assay for the detection of DNA-binding molecules; Cynthia A. Edwards, et al., 435/6, 91.2; 436/501 [IMAGE AVAILABLE]
- 11. 5,725,804, Mar. 10, 1998, Non-crosslinked protein particles for therapeutic and diagnostic use; Richard C. K. Yen, 252/314, 311; 424/484, 491; 514/776, 937, 965 [IMAGE AVAILABLE]
- 12. 5,716,780, Feb. 10, 1998, Method of constructing sequence-specific DNA-binding molecules; Cynthia A. Edwards, et al., 435/6; 436/501 [IMAGE AVAILABLE]
- 13. 5,702,727, Dec. 30, 1997, Compositions and methods for the oral delivery of active agents; Alfred A. Amkraut, et al., 424/491, 489, 490; 428/402; 514/2, 773 [IMAGE AVAILABLE]
- 14. 5,679,511, Oct. 21, 1997, CDNA clones for a regulatory protein in the melanin-production pathway; Byoung Se Kwon, 435/6, 320.1; 530/350; 536/23.2, 23.5 [IMAGE AVAILABLE]
- 15. 5,677,278, Oct. 14, 1997, Truncated keratinocyte growth factor (KGF) having increased biological activity; Denis J. Gospodarowicz, et al., 514/12, 2, 8; 530/350, 397, 399 [IMAGE AVAILABLE]
- 16. 5,674,728, Oct. 7, 1997, Aspergillus niger vacuolar aspartyl protease; Frank Buxton, et al., 435/225, 69.1, 172.3, 252.3, 254.11, 254.3, 320.1; 536/23.2 [IMAGE AVAILABLE]
- 17. 5,670,488, Sep. 23, 1997, **Adenovirus vector** for gene therapy; Richard J. Gregory, et al., 514/44; 424/93.2; 435/320.1; 935/62 [IMAGE AVAILABLE]
- 18. 5,650,299, Jul. 22, 1997, Cells producing stem cell proliferation factor; Michael J. P. Lawman, et al., 435/70.1, 71.1, 325, 354, 372; 530/350, 351 [IMAGE AVAILABLE]
- 19. 5,645,829, Jul. 8, 1997, Mesothelial cell gene therapy; Ty Robert Shockley, et al., 424/93.21, 572; 435/172.3, 366, 371; 514/44; 935/62, 70, 71 [IMAGE AVAILABLE]
- 20. 5,641,750, Jun. 24, 1997, Methods for **treating** photoreceptors using glial cell line-derived **neurotrophic** factor (GDNF) protein product; Jean-Claude Louis, 514/12; 435/69.1, 69.4 [IMAGE AVAILABLE]
- 21. 5,641,749, Jun. 24, 1997, Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product; Qiao Yan, et al., 514/12; 435/69.1, 69.4 [IMAGE AVAILABLE]
- 22. 5,624,912, Apr. 29, 1997, Method of **treating** HIV infection and related secondary infections with defibrotide; Arsinur Burcoglu, et al., 514/44, 924, 934 [IMAGE AVAILABLE]
- 23. 5,620,708, Apr. 15, 1997, Compositions and methods for the oral

- 24. 5,616,311, Apr. 1, 1997, Non-crosslinked protein particles for therapeutic and diagnostic use; Richard C. K. Yen, 424/1.33, 1.29, 1.37, 484, 499; 427/2.14, 2.21, 213.3, 213.33; 428/402.2, 402.24; 435/177; 935/54 [IMAGE AVAILABLE]
- 25. 5,599,712, Feb. 4, 1997, Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy; Joel S. Greenberger, 435/267; 424/93.2, 93.21; 435/320.1; 514/44 [IMAGE AVAILABLE]
- 26. 5,578,461, Nov. 26, 1996, Gene manipulation and expression using genomic elements; Stephen Sherwin, et al., 435/69.1, 172.3, 244, 320.1; 536/23.1, 24.1; 935/28, 33, 55 [IMAGE AVAILABLE]
- 27. 5,578,444, Nov. 26, 1996, Sequence-directed DNA-binding molecules compositions and methods; Cynthia A. Edwards, et al., 435/6, 7.23; 536/23.1; 935/76, 77 [IMAGE AVAILABLE]
- 28. 5,571,797, Nov. 5, 1996, Method of inducing gene expression by ionizing radiation; Tsuneya Ohno, et al., 514/44; 424/1.11, 1.49, 1.61, 1.65, 1.69, 93.2, 93.21, 450; 435/69.1, 69.5, 172.3, 320.1; 536/24.1; 935/6, 34, 59, 62 [IMAGE AVAILABLE]
- 29. 5,561,053, Oct. 1, 1996, Method for selecting high-expressing host cells; Craig W. Crowley, 435/69.1, 172.3, 320.1, 358; 536/23.2 [IMAGE AVAILABLE]
- 30. 5,506,133, Apr. 9, 1996, **Superoxide dismutase-4**; Gu-Liang Yu, et al., 435/365, 252.3, 254.11, 320.1; 536/23.2 [IMAGE AVAILABLE]
- 31. 5,496,731, Mar. 5, 1996, Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy; Hong-Ji Xu, et al., 435/320.1; 514/44; 536/23.5 [IMAGE AVAILABLE]
- 32. 5,460,950, Oct. 24, 1995, Expression of PACE in host cells and methods of use thereof; Philip J. Barr, et al., 435/69.1, 69.6, 219, 226, 252.3, 320.1; 935/28, 32, 60, 69, 70, 71 [IMAGE AVAILABLE]
- 33. 5,438,121, Aug. 1, 1995, Brain derived **neurotrophic** factor; Yves-Alain Barde, et al., 530/399; 435/69.1; 530/350, 387.9, 389.2; 536/23.51 [IMAGE AVAILABLE]
- 34. 5,426,181, Jun. 20, 1995, DNA encoding cytokine-induced protein, TSG-14; Tae H. Lee, et al., 536/23.5; 435/69.1, 252.3, 320.1; 536/23.1 [IMAGE AVAILABLE]
- 35. 5,386,013, Jan. 31, 1995, Tumor necrosis factor-induced protein TSG-6; Tae H. Lee, et al., 530/350; 435/69.1; 530/351 [IMAGE AVAILABLE]
- 36. 5,283,188, Feb. 1, 1994, Isolation, purification, characterization, cloning and sequencing of N.sup..alpha. -acetyltransferase; John A. Smith, et al., 435/193, 69.1, 252.3, 252.31, 320.1; 536/23.2; 935/14, 28, 29, 34, 39, 68, 74 [IMAGE AVAILABLE]
- 37. 5,223,421, Jun. 29, 1993, Identification of methionine N.alpha.-acetyltransferase; John A. Smith, et al., 435/193, 255.2, 803, 814, 815, 942 [IMAGE AVAILABLE]
- 38. 5,223,408, Jun. 29, 1993, Method for making variant secreted proteins with altered properties; David V. Goeddel, et al., 435/69.3, 69.4, 69.52, 69.6, 69.7, 172.3, 189, 195, 215, 216, 226 [IMAGE AVAILABLE]

- 40. 5,210,024, May 11, 1993, Isolation of strains of Saccharomyces cerevisiae having altered .alpha.-acetyltransferase activity; John A. Smith, et al., 435/69.1, 193, 252.3, 254.2, 358, 364, 418, 419; 536/23.2 [IMAGE AVAILABLE]
- 41. 5,128,459, Jul. 7, 1992, Isolation, purification, characterization, cloning and sequencing of N alpha-acetyltransferase; John A. Smith, et al., 435/252.3, 320.1; 536/23.2; 935/11, 22, 66 [IMAGE AVAILABLE]
- 42. 4,966,848, Oct. 30, 1990, Isolation, purification, characterization, cloning and sequencing of N .alpha.-acetyltransferase; John A. Smith, et al., 435/193, 942 [IMAGE AVAILABLE]
- 43. 4,935,349, Jun. 19, 1990, Expression of higher eucaryotic genes in aspergillus; Gary L. McKnight, et al., 435/69.5, 69.6, 171, 172.3, 212, 254.3, 320.1, 913, 917; 530/351, 388.1, 866, 867; 536/23.51, 23.53, 24.1; 935/6, 10, 24, 34, 36, 48, 60, 68 [IMAGE AVAILABLE]